Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Clinical Genetics|August 23, 2006
Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort studyK-A Phillips, M A Jenkins, G J Lindeman, et al.
Breast Cancer Research and Treatment|August 19, 2011
Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive familiesS L Harvey, R L Milne, S A McLachlan, et al.
Gynecologic Oncology|November 1, 1988
Ovarian carcinoma: abdominopelvic irradiation following reexplorationH J Solomon, K H Atkinson, J V Coppleson, et al.
The Medical Journal of Australia|May 19, 1997
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapyM Michael, J F Bishop, J A Levi, et al.
Familial Cancer|March 23, 2011
Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancerB E Kiely, M L Friedlander, R L Milne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase InhibitorAngelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2008
Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancerK M Field, M A Jenkins, M L Friedlander, et al.
Familial Cancer|March 13, 2017
Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancerY C Lee, M Bressel, P Grant, et al.
Gynecologic Oncology|December 15, 2019
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)F T Roncolato, R L O'Connell, F Joly, et al.
Pageof 6